Singapore: Teijin Pharma, the core company of the Teijin Group's healthcare business, and Ipsen launched Somatuline 60/90/120 mg for subcutaneous injection in Japan for the treatment of acromegaly and pituitary gigantism (when response to surgical therapies is not satisfactory or surgical therapies are difficult to perform). In Japan, Teijin Pharma holds the rights to develop and market the drug.

Somatuline is a synthetic somatostatin analog developed by Ipsen approved in more than 60 countries worldwide. In Japan, Somatuline is available in a differentiated and enhanced presentation with a pre-filled syringe that does not need reconstitution and with a retractable needle that enhances safety for caregivers; Somatuline's long-lasting effects enable one administration every four weeks.

Mr Kentaro Arao, president of Teijin Pharma said, "Somatuline, used in more than 60 countries worldwide, is highly regarded by the medical profession and patients for its long-lasting effects and user-friendly dosing devices."

"We are pleased to launch Somatuline in Japan, confident that it will offer patients a beneficial treatment option to control the symptoms of acromegaly, or pituitary gigantism, for improved quality of life," he added.

Mr Christophe Jean, Ipsen's executive vice-president of operations, said that, "We are privileged to have Teijin as our partner in Japan and pleased that Somatuline is now also available to Japanese patients suffering from acromegaly and pituitary gigantism."